02:28 PM EDT, 05/23/2024 (MT Newswires) -- GSK (GSK) won a jury verdict in Chicago after a Cook County, Illinois, circuit court concluded that discontinued heartburn drug Zantac wasn't a cause of a woman's cancer, Reuters reported.

Angela Valadez alleged that long-term use of Zantac had caused her colon cancer, but the jury ruled the Illinois resident, age 89, didn't prove her claim, Reuters said.

Attorneys for Valadez sought $640 million for her suffering, Reuters said. Boehringer Ingelheim was the other defendant in the trial.

GSK discontinued Zantac following claims that the drug's active ingredient ranitidine might react to form a dangerous carcinogen called NDMA, Reuters said.

Mikal Watts, a Valadez attorney, said he was confident the companies would be held liable in future Zantac trials, Reuters reported. "This is a marathon, not a sprint," he said, according to the report.

The case marked the first trial out of thousands of lawsuits making similar allegations, Reuters said.

GSK did not immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 45.10, Change: -0.68, Percent Change: -1.49